4-[(1R,3R,4R)-3-(4-bromophenyl)-4-{[(1R)-1-(4-fluorophenyl)ethyl]-carbamoyl}cyclohexyl]morpholine | 1350710-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(1R,3R,4R)-3-(4-bromophenyl)-4-{[(1R)-1-(4-fluorophenyl)ethyl]-carbamoyl}cyclohexyl]morpholine
• 英文别名: (1R,2R,4R)-2-(4-bromophenyl)-N-[(1R)-1-(4-fluorophenyl)ethyl]-4-morpholin-4-ylcyclohexane-1-carboxamide
• CAS: 1350710-65-4
• 化学式: C₂₅H₃₀BrFN₂O₂
• 分子量: 489.428
• InChiKey: YVDZLBQGUSUPTC-BMZZKGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 2-( 1H-7-azabenzotniazol-1-yl)-1,1,3,3-tetrarmethyluroniumhexafluorophosphate methanaminium 、 水 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 二甲胺 为溶剂， 反应 24.0h， 生成 4-[(1R,3R,4R)-3-(4-bromophenyl)-4-{[(1R)-1-(4-fluorophenyl)ethyl]-carbamoyl}cyclohexyl]morpholine
  参考文献：
  名称：

  Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors

  摘要：

  The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane- based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.094

文献信息

• [EN] NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROLYLCARBOXYPEPTIDASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011146300A1

  公开（公告）日：2011-11-24

  Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

  结构式I的化合物是脯氨酸羧肽酶（PrCP）的抑制剂。本发明的化合物可用于预防和治疗与PrCP酶活性相关的疾病，如异常代谢，包括肥胖、糖尿病、代谢综合征、肥胖相关疾病和糖尿病相关疾病。
• NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS
  申请人：Shen Dong-Ming

  公开号：US20130217660A1

  公开（公告）日：2013-08-22

  Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

  结构式I的化合物是脯氨酰羧肽酶(PrCP)的抑制剂。本发明的化合物可用于预防和治疗与PrCP酶活性相关的病症，如异常代谢，包括肥胖症、糖尿病、代谢综合征、与肥胖有关的疾病和与糖尿病有关的疾病。
• US8669252B2
  申请人：——

  公开号：US8669252B2

  公开（公告）日：2014-03-11
• Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors
  作者：John S. Debenham、Thomas H. Graham、Andreas Verras、Yong Zhang、Matthew J. Clements、Jeffrey T. Kuethe、Christina Madsen-Duggan、Wensheng Liu、Urmi R. Bhatt、Dunlu Chen、Qing Chen、Margarita Garcia-Calvo、Wayne M. Geissler、Huaibing He、Xiaohua Li、JeanMarie Lisnock、Zhu Shen、Xinchun Tong、Elaine C. Tung、Judyann Wiltsie、Suoyu Xu、Jeffrey J. Hale、Shirly Pinto、Dong-Ming Shen

  DOI：10.1016/j.bmcl.2013.09.094

  日期：2013.12

  The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane- based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose. (C) 2013 Elsevier Ltd. All rights reserved.